FDA Approves Higher SPINRAZA Dose for Spinal Muscular Atrophy

The new regimen reflects progress in treating this rare genetic disease.

Mar. 30, 2026 at 3:10pm

Got story updates? Submit your updates here. ›

The U.S. Food and Drug Administration (FDA) has approved a higher dose regimen of the drug SPINRAZA for the treatment of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that affects muscle strength and movement. This new dosing represents an advancement in the treatment of SMA.

Why it matters

SMA is a debilitating condition that can severely impact a patient's quality of life and life expectancy. The approval of a higher dose of SPINRAZA provides an important new treatment option that may help improve outcomes for those living with SMA.

The details

SPINRAZA, developed by Biogen, is an antisense oligonucleotide therapy that works by increasing production of a protein critical for motor neuron function. The new FDA-approved regimen allows for higher doses to be administered, which may lead to greater therapeutic benefit for SMA patients.

  • The FDA approved the higher dose regimen of SPINRAZA on March 30, 2026.

The players

Muscular Dystrophy Association (MDA)

A nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, ALS, and related diseases.

Biogen

A multinational biotechnology company that developed the drug SPINRAZA for the treatment of spinal muscular atrophy.

Got photos? Submit your photos here. ›

What they’re saying

“This new dosing regimen for SPINRAZA represents an important advancement in the treatment of spinal muscular atrophy.”

— Dr. Valerie Cwik, Chief Medical and Scientific Officer, Muscular Dystrophy Association

What’s next

Patients and their healthcare providers will work closely to determine if the higher dose regimen of SPINRAZA is appropriate for their individual treatment plan.

The takeaway

The FDA's approval of a higher dose of SPINRAZA is a significant milestone in the ongoing effort to improve outcomes for those living with the debilitating effects of spinal muscular atrophy, a rare and life-threatening genetic disease.